KDventures AB Stock

KDV B

SE0002190926

Investment Management & Fund Operators

Market Closed - Nasdaq Stockholm 12:00:00 2026-09-22 EDT			5-day change	1st Jan Change
0.2660 ^SEK	-1.30%		+0.19%	-38.99%

09-15	KD Ventures: Umecrine completes patient phase in PBC study	FW
09-07	Block trade of 0.6 percent of the capital executed in KD Ventures	FW

Analysts' recommendations: KDventures AB

05-11	Redeye: KD Ventures trading at a steep discount to NAV	FW
05-11	Redeye initiates coverage of KD Ventures with a fair value of SEK 1.0 per share	FW
11-17	DNB Carnegie Lowers Target Value for Karolinska Development to SEK 1.4-2.1 per Share	FW
11-04	Karolinska Development's Modus Therapeutics gets approval for 2nd part of phase 2 study	RE
11-04	Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemia	CI

More recommendations

Managers and Directors: KDventures AB

Manager	Title	Age	Since
Viktor Drvota CEO	Chief Executive Officer	61	2017-05-31
Hans Christopher Toll DFI	Director of Finance/CFO	58	2022-09-30
Mikaela Sörman CIO	Chief Investment Officer	-	-

Director	Title	Age	Since
Theresa Y. Y. Tse BRD	Director/Board Member	33	2017-11-27
Anna Lefevre Skjöldebrand BRD	Director/Board Member	57	2021-02-18
Benjamin Toogood CHM	Chairman	50	2024-12-17

More insiders

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâ€™s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâ€™s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Employees

Sector

Investment Management & Fund Operators

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-22	SEK 0.2660	-1.30%	800,164
26-09-21	SEK 0.2695	-3.41%	156,668
26-09-18	SEK 0.2790	+2.20%	2,329,634
26-09-17	SEK 0.2730	-1.80%	373,055
26-09-16	SEK 0.2780	+4.71%	867,575

Delayed Quote Nasdaq Stockholm

More quotes

Annual profits - Rate of surprise

Company calendar

Market Cap	202M 20.48M 17.89M 16.82M 15.35M 28.8M 1.96B 28.81M 77.89M 1B 76.89M 75.21M 3.22B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	202M 20.48M 17.89M 16.82M 15.35M 28.8M 1.96B 28.81M 77.89M 1B 76.89M 75.21M 3.22B	EV / Sales 2026 *	-0.42x	EV / Sales 2027 *	2.99x
Free-Float	56.57%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	KDV B	Delayed
CBOE	KDEVs	Real-time
CBOE	0P3C	Real-time
Deutsche Boerse AG	2I9	Delayed
Börse Stuttgart	2I9	Delayed
Boerse Muenchen	2I9	Real-time

09-15	KD Ventures: Umecrine completes patient phase in PBC study	FW
09-07	Block trade of 0.6 percent of the capital executed in KD Ventures	FW
09-07	KD Ventures portfolio company Umecrine Cognition receives two patent approvals in the US	FW
09-04	KD Ventures portfolio company Modus Therapeutics carries out a directed share issue	FW
08-28	KDventures AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-28	KD Ventures reports lower net asset value	FW
08-03	Umecrine Cognition has enrolled the last patient in study	FW
07-09	KD Ventures portfolio company PharmNovo raises SEK 39m	FW
06-25	KDventures: Anacardio's heart failure study published in The Lancet	FW
06-23	KD Ventures: Umecrine study remains on track after interim analysis	FW
06-18	KD Ventures board member Anders Bladh increases his stake	FW
06-18	KDventures Raises SEK24 Million via Directed Share Issue	MT
06-18	KD Ventures raises 23.9m SEK via private placement at a 15.3 percent discount	FW

09-15	KDventures : rsquo; portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis	PU
09-07	KDventures' : portfolio company Umecrine Cognition receives two Notices of Allowance in the US for second-generation GAMSA compounds	PU
09-07	KDventures’ portfolio company Umecrine Cognition receives two Notices of Allowance in the US for second-generation GAMSA compounds	AQ
09-04	KDventures portfolio company Modus Therapeutics carries out a directed issue of MSEK 7.6	AQ
08-28	Interim Report - January-June 2026	AQ

1 day	-1.30%
1 week	+0.19%
Current month	+20.91%
1 month	+13.92%
3 months	+4.72%
6 months	+14.41%
Current year	-38.99%

KDventures AB Stock

Stocks

KDV B

SE0002190926

Investment Management & Fund Operators

Valuation: KDventures AB

Chart: KDventures AB

Latest news: KDventures AB

Analysts' recommendations: KDventures AB

Press Releases: KDventures AB

Quotes and Performance

Price Extremes

Managers and Directors: KDventures AB

Latest insider transactions

Private Equity

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	0.25	0.28
1 month	0.21	0.28
Current year	0.2	0.45
1 year	0.2	0.94
3 years	0.2	1.95
5 years	0.2	11.24
10 years	0.2	11.24

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/27/23	Johan Dighed	Buy	General Counsel	50,000	0.0187%
9/30/22	Johan Dighed	Buy	General Counsel	40,187	0.0150%
3/8/22	Benjamin Toogood	Buy	Chairman	64,001	0.0367%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KDVENTURES AB	-1.30%	+0.19%	-70.35%	-82.86%	20.79M
EQT AB	-0.82%	-0.50%	-10.81%	+38.50%	36.1B
PARTNERS GROUP HOLDING AG	+0.55%	-0.54%	-41.61%	-39.15%	19.39B
CVC CAPITAL PARTNERS PLC	-0.16%	-2.60%	-14.69%	-	15.23B
ONEX CORPORATION	+1.25%	+1.60%	-10.87%	+37.28%	5.91B
BRIDGEPOINT GROUP PLC	+0.58%	+9.63%	-2.38%	+63.16%	3.65B
RATOS AB	+0.79%	+2.42%	+6.49%	+11.03%	1.26B
INVESTCORP CAPITAL PLC	-1.27%	-2.52%	-5.49%	-	932M
MEDCAP AB	+1.03%	+2.28%	-9.26%	+89.12%	812M
ALARIS EQUITY PARTNERS INCOME TRUST	+0.17%	+3.74%	+23.31%	+61.22%	775M
Average	+0.06%	-0.01%	-13.57%	+22.29%	8.41B
Weighted average by Cap.	-0.15%	-2.18%	-17.62%	+17.87%

	2026 *	2027 *
Net sales	-476M -48.33M -42.23M -39.69M -36.22M -67.98M -4.62B -68M -184M -2.36B -181M -178M -7.61B	67.4M 6.84M 5.98M 5.62M 5.12M 9.62M 654M 9.62M 26.01M 334M 25.68M 25.11M 1.08B
Net income	-497M -50.41M -44.05M -41.4M -37.78M -70.91M -4.82B -70.92M -192M -2.46B -189M -185M -7.93B	45.4M 4.61M 4.02M 3.78M 3.45M 6.48M 440M 6.48M 17.52M 225M 17.3M 16.92M 725M
Net Debt	-	-